Clinical trials in a dish: A perspective on the coming revolution in drug development

June 5, 2018, SLAS (Society for Laboratory Automation and Screening)
Clinical trials in a dish: A perspective on the coming revolution in drug development
The emergence of various hiPSC-derived cell types (cardiac, neuronal, hepatic) allows, for the first time, to combine the strengths of human diversity with the in vitro assessment of susceptibility to drug-induced toxicity. Credit: Coyne Scientific

A new SLAS Discovery article available now for free ahead-of-print, offers perspective from researchers at Coyne Scientific (Atlanta, GA) about Clinical Trials in a Dish (CTiD), a novel strategy that bridges preclinical testing and clinical trials.

The pharmaceutical industry is facing unprecedented challenges as the cost of developing new drugs reaches unsustainable levels, fueled in large part by high attrition rates in clinical development. This new CTiD platform allows pharmaceutical companies to test, at the population level, novel drugs on patient cells before moving into actual . Because current preclinical strategies don't follow this principle, CTiD offers the potential to significantly impact and development.

Recent demonstrations show various human induced pluripotent stem cell-derived (hiPSCs) cell types (cardiac, neuronal, hepatic) recapitulate a specific individual's response (rather than that of a generic human being) and have opened up new avenues that support the concept of screening for cell-based safety and toxicity at the level of a population. The concept of CTiD is to satisfy, in an in vitro setting, the defining biological truth that establishes the need for a multi-patient clinical trial, which is that drug responses vary by human. CTiD studies are efficient, allow the study of a range of clinical doses, and can be executed at a fraction of the cost outside of the rigid and heavily regulated clinical testing environment.

CTiD studies are poised to revolutionize thinking about practical, immediate and near-term applications in the field of drug discovery and development. CTiD can lead to insights that cannot be obtained so early and economically in drug by any other approach. Although still requiring improvements and enhancements, CTiD offers to refine the selection of drugs to move into , leading to reduced attrition and enabling safe drugs that address unmet medical needs to reach patients more quickly.

Explore further: Application of human induced pluripotent stem cells in precision medicine for hereditary diseases

More information: Bernard Fermini et al, Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development, SLAS DISCOVERY: Advancing Life Sciences R&D (2018). DOI: 10.1177/2472555218775028

Related Stories

Application of human induced pluripotent stem cells in precision medicine for hereditary diseases

May 8, 2018
Researchers at Li Ka Shing Faculty of Medicine of The University of Hong Kong (HKU) have successfully demonstrated the use of human induced pluripotent stem cells (hiPSCs) from patients' skin cells for therapeutic drug testing. ...

Stem cell-based screening methods may predict heart-related side effects of drugs

September 19, 2016
Coaxing stem cells from patients to become heart cells may help clinicians personalize drug treatments and prevent heart-related toxicity.

TB Alliance moves two novel tuberculosis drugs into human trials

October 11, 2017
TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted "Investigative New Drug" status by the U.S. Food and ...

Comparing cancer drug effectiveness from cells to mice to man

September 6, 2017
Science is very good at determining how drugs work in experimental models. New research out of Dartmouth's Norris Cotton Cancer Center led by Alan Eastman, PhD, helps to bridge the gap when it comes to ensuring that drugs ...

Are women really under-represented in clinical trials?

January 11, 2018
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and ...

Why computer simulations should replace animal testing for heart drugs

March 27, 2018
Safety is imperative before new medicines are given to patients – which is why drugs are tested on millions of animals worldwide each year to detect possible risks and side effects. But research shows computer simulations ...

Recommended for you

LincRNAs identified in human fat tissue

June 21, 2018
A large team of researchers from the U.S. and China has succeeded in identifying a number of RNA fragments found in human fat tissue. In their paper published in the journal Science Translational Medicine the group describes ...

Scientists solve the case of the missing subplate, with wide implications for brain science

June 21, 2018
The disappearance of an entire brain region should be cause for concern. Yet, for decades scientists have calmly maintained that one brain area, the subplate, simply vanishes during the course of human development. Recently, ...

Key molecule of aging discovered

June 21, 2018
Every cell and every organism ages sooner or later. But why is this so? Scientists at the German Cancer Research Center in Heidelberg have now discovered for the first time a protein that represents a central switching point ...

Compound made inside human body stops viruses from replicating

June 20, 2018
The newest antiviral drugs could take advantage of a compound made not by humans, but inside them. A team of researchers has identified the mode of action of viperin, a naturally occurring enzyme in humans and other mammals ...

Research reveals zero proof probiotics can ease your anxiety

June 20, 2018
If you're expecting probiotics to reduce your anxiety, it might be time to put down that yogurt spoon—or supplement bottle—and call a professional instead.

Long-term estrogen therapy changes microbial activity in the gut, study finds

June 20, 2018
Long-term therapy with estrogen and bazedoxifene alters the microbial composition and activity in the gut, affecting how estrogen is metabolized, a new study in mice found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.